Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
November 07, 2024 09:15 ET
|
Xilio Therapeutics, Inc.
Combination of vilastobart and atezolizumab demonstrated encouraging early evidence of anti-tumor activity, including unconfirmed partial responses observed in two patients with difficult-to-treat,...
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
November 07, 2024 09:05 ET
|
Xilio Therapeutics, Inc.
Will present initial Phase 1C dose escalation data for vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab, in a late-breaker poster presentation at the...
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
October 30, 2024 09:01 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
October 04, 2024 09:05 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2024 16:15 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
August 28, 2024 16:01 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
August 08, 2024 07:30 ET
|
Xilio Therapeutics, Inc.
Initiated enrollment in Phase 2 clinical trial of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS...
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
June 13, 2024 16:05 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
May 14, 2024 07:30 ET
|
Xilio Therapeutics, Inc.
Expect to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the...
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
April 01, 2024 16:05 ET
|
Xilio Therapeutics, Inc.
On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS...